Figure 2
From: Serum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study
Serum levels of active lipid mediators and ω3-PUFAs differentially expressed in healthy controls or COVID-19 patients with different severity. COVID-19 patients were divided into three groups: mild, moderate, and severe pulmonary involvement. Panels represent concentrations of prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), 14-hydroxy docosahexaenoic acid (14-HDHA), maresin 2 (MaR2), resolvin D4 (RvD4), resolvin D5 (RvD5), and resolvin E1 (RvE1), respectively, in mentioned groups. P-values were obtained by performing a Mann–Whitney U test. Only lipid mediators with P < 0.05 by Kruskal–Wallis test (Table 3) were represented.
